Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
IONS 
Ionis Pharmaceuticals Inc (IONS)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: IONS (4-star) is a STRONG-BUY. BUY since 111 days. Simulated Profits (115.81%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $76.91
1 Year Target Price $76.91
| 12 | Strong Buy |
| 5 | Buy |
| 8 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 141.15% | Avg. Invested days 74 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.25B USD | Price to earnings Ratio - | 1Y Target Price 76.91 |
Price to earnings Ratio - | 1Y Target Price 76.91 | ||
Volume (30-day avg) 26 | Beta 0.33 | 52 Weeks Range 23.95 - 72.15 | Updated Date 10/14/2025 |
52 Weeks Range 23.95 - 72.15 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.41% | Operating Margin (TTM) 30.93% |
Management Effectiveness
Return on Assets (TTM) -5.87% | Return on Equity (TTM) -59.91% |
Valuation
Trailing PE - | Forward PE 90.91 | Enterprise Value 10032371063 | Price to Sales(TTM) 11.92 |
Enterprise Value 10032371063 | Price to Sales(TTM) 11.92 | ||
Enterprise Value to Revenue 10.63 | Enterprise Value to EBITDA -22.08 | Shares Outstanding 159391229 | Shares Floating 158082627 |
Shares Outstanding 159391229 | Shares Floating 158082627 | ||
Percent Insiders 0.64 | Percent Institutions 108.3 |
Upturn AI SWOT
Ionis Pharmaceuticals Inc
Company Overview
History and Background
Ionis Pharmaceuticals Inc. (IONS) was founded in 1989 by Dr. Stanley Crooke. It pioneered antisense technology to develop RNA-targeted therapeutics. Key milestones include the FDA approval of Vitravene in 1998 and Spinraza in 2016.
Core Business Areas
- Drug Discovery and Development: Ionis focuses on discovering and developing antisense oligonucleotide (ASO) therapies for various diseases.
- Commercialization: Ionis commercializes some of its drugs directly and partners with other pharmaceutical companies for commercialization.
- Strategic Partnerships: Ionis collaborates with companies such as Biogen, Roche, and AstraZeneca to expand its pipeline and market reach.
Leadership and Structure
Brett P. Monia serves as the CEO. The company is structured around research and development, commercial, and administrative functions.
Top Products and Market Share
Key Offerings
- Spinraza: Spinraza (nusinersen) is used to treat spinal muscular atrophy (SMA). The drug is marketed by Biogen. Competitors include Novartis (Zolgensma) and Roche (Evrysdi). Global Spinraza revenue for Biogen was approximately $1.5 billion in 2023.
- Qalsody: Qalsody (tofersen) is for the treatment of amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Competitors include Amylyx Pharmaceuticals Inc. (Relyvrio).
- Wainua: Wainua (eplontersen) is for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN). Competitors include Alnylam Pharmaceuticals (Onpattro).
Market Dynamics
Industry Overview
The pharmaceutical industry is driven by innovation, regulatory approvals, and market access. RNA-targeted therapeutics are a growing segment.
Positioning
Ionis is a leader in antisense technology, with a strong pipeline and established partnerships, giving it a competitive advantage in developing novel therapies.
Total Addressable Market (TAM)
The TAM for neurological and rare diseases is substantial, estimated in the hundreds of billions of dollars. Ionis is positioned to capture a significant share through its innovative RNA-targeted therapies.
Upturn SWOT Analysis
Strengths
- Pioneering antisense technology
- Strong pipeline of drug candidates
- Established partnerships with major pharmaceutical companies
- FDA-approved drugs with proven efficacy
- Expertise in RNA-targeted therapeutics
Weaknesses
- Reliance on partnerships for commercialization
- High R&D costs
- Potential for competition from other RNA-based therapies
- Dependence on regulatory approvals
Opportunities
- Expanding pipeline to address more diseases
- Developing next-generation antisense technologies
- Strategic acquisitions to broaden capabilities
- Further collaborations to increase market reach
- Increased demand for personalized medicine
Threats
- Regulatory hurdles and delays
- Competition from other pharmaceutical companies
- Patent expirations
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- ALNY
- MRNA
- LLY
- VRTX
Competitive Landscape
Ionis has a competitive advantage in antisense technology but faces competition from other RNA-based therapies and established pharmaceutical companies. Alnylam Pharmaceuticals (ALNY) and Moderna (MRNA) are major competitors in the RNA therapeutics space. Other pharmaceutical companies like Eli Lilly (LLY) and Vertex Pharmaceuticals (VRTX) could also be viewed as general competitors in disease treatment.
Major Acquisitions
Akcea Therapeutics
- Year: 2020
- Acquisition Price (USD millions): 500
- Strategic Rationale: The acquisition of Akcea Therapeutics aimed to consolidate Ionis's control over its RNA-targeted therapies and streamline operations.
Growth Trajectory and Initiatives
Historical Growth: Ionis has experienced revenue growth driven by product sales and partnership revenue.
Future Projections: Analysts project continued growth driven by pipeline expansion and potential new drug approvals. Consensus estimates vary.
Recent Initiatives: Recent initiatives include expanding its pipeline with new drug candidates and strengthening partnerships with Biogen and other pharmaceutical companies.
Summary
Ionis Pharmaceuticals is a leader in antisense technology with a strong pipeline, but it relies heavily on partnerships. Successful commercialization and pipeline advancement drive growth. Regulatory hurdles and competition are ongoing challenges. Ionis should prioritize expanding its pipeline and managing partnership dependencies for sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Ionis Pharmaceuticals Inc. SEC Filings
- Company website
- Analyst reports
- Press releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ionis Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 1991-05-17 | Founder, CEO & Director Dr. Brett P. Monia Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1069 | Website https://www.ionis.com |
Full time employees 1069 | Website https://www.ionis.com | ||
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.